Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.90 |
| ▸ | DNM2 | P50570 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5791298 | 0.98 | TLR8 (0.88) | TLR8DNM2ALDH1A1LMNATP53 | |
| SCHEMBL20434306 | 0.95 | TLR8 (1.00) | TLR8DNM2ALDH1A1LMNATP53 | |
| SCHEMBL8585646 | 0.88 | TLR8 (0.81) | TLR8DNM2ALDH1A1LMNATP53 | |
| SCHEMBL26345520 | 0.86 | TLR8 (0.78) | TLR8ALDH1A1LMNATP53TSHR | |
| SCHEMBL29442374 | 0.86 | TLR8 (0.78) | TLR8ALDH1A1LMNATP53TSHR | |
| SCHEMBL30263108 | 0.83 | TLR8 (0.64) | TLR8DNM2TLR7CYP2D6HRH4 | |
| SCHEMBL29156884 | 0.83 | TLR8 (0.64) | TLR8DNM2TLR7CYP2D6HRH4 | |
| SCHEMBL11752857 | 0.82 | CYP2D6 (0.64) | TLR8DNM2ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5792943 | 0.81 | TLR8 (0.66) | TLR8DNM2ALDH1A1MEN1KMT2A | |
| SCHEMBL13309860 | 0.81 | TLR8 (0.61) | TLR8DNM2ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4043460-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2022-08-17 | — | — | EP | disclosed |
| CN-113966326-A | Water soluble adjuvants | 大日本住友制药株式会社 | 2022-01-21 | — | — | CN | disclosed |
| US-8765939-B2 | Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers | ASTRAZENECA AB (SE) | 2014-07-01 | — | — | US | disclosed |
| US-20130045955-A1 | NOVEL COMPOUNDS | BENNETT NICHOLAS J (GB) | 2013-02-21 | — | — | US | disclosed |
| EP-2222648-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2013-01-09 | — | — | EP | disclosed |
| US-8268990-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| EP-2222648-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | AstraZeneca AB (SE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | TLR8 4435/4885DNM2 4549/4885ALDH1A1 241/4885 |
| US-20130045955-A1 | NOVEL COMPOUNDS | ABCG2, F12, CFTR | TLR8 4332/4885DNM2 4586/4885ALDH1A1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.